Results

An instant improvement

The stimulation leads to the Meibomian glands returning to their normal function in a very short time (a couple of hours) following the treatment.

In the long run

The treatment effects last 6 months to 3 years after the 3rd to 4th sessions.

In 60% of cases, effects persist beyond 3 years after the treatment.

According to the Oxford scheme (0,I, II, III, IV), patients with lower grade (1 and 2) are “easy” candidates that go down from 1 to 2 grades after the first 3 sessions.

Figure: Oxford grading system

Scientifically proven efficiency by 4 clinical studies

1 – Clinical trial in France, 2012

Study:

Dr Christian Malbrel, Ophthalmologist in Reims, France, undertook a clinical study in 2012 on 150 patients with MGD.

Results:

Results show 90% satisfaction rate after a serie of 3 treatments on day 1, 15 and 45.

Read more

2 – Clinical trial in New Zealand, 2014

Study:

Associate Professor Jennifer P. Craig from the Ocular Surface Laboratory within The University of Auckland’s Department of Ophthalmology, has published results of a prospective, double-masked clinical study using E-Eye technology for the treatment of MGD. This study has been published in the Association for Research and Vision in Ophthalmology’s (ARVO’s) journal of Investigative Ophthalmology & Visual Science.

Results:

Here are the results 45 days after 3 treatments:

• Significant improvement in the Non-Invasive Tear Break Up Time (NIBUT) in the treated eye but not in the control one.
• Significant improvement of the tear Lipid Layer Grade (LLG) measured with a TearScope.
• 86% of participants noted reduced symptoms in the treated eye (SPEED score).

Figure: Non invasive tear break-up time of the treated and control improved from BL, with only one eye treated, bodes well for eye at each of the four visits. Non invasive tear break-up time was higher at D45 relative to BL in the treated eye (P < 0.001), but not in the control eye (P¼ 0.56). Additionally, NIBUT was significantly higher in the treated eye compared with the control eye at D45 (P < 0.001).
*Significant difference between groups at P < 0.005. Error bars denote SEM.
Read more

3 – Clinical trial in China, Third Hospital of Pekin University, 2014

Study:

Evaluation of the safety and affectiveness of the Controlled Discharged Xenon Flash Lamp (IRPL) device in the treatment of Meibomian Gland Dysfunction caused dry eye.
Read the official publication

Results:

Using Controlled Discharge Xenon Flash Lamp device treatment (energy level 13.0J/cm2), the dry eye symptoms were significantly relieved in patients who suffered from Meibomian Gland Dysfunction caused dry eye. The morphology of the palebral margin, the meibomian gland opening obstruction and the meibomian gland quantity were also improved. The difference between prior and post treatment was statistically significant. In addition, the Controlled Discharge Xenon Flash Lamp device therapy could improve the tear film quality, and prolonged the tear break up time. Following 4 consecutive treatments, the improvement to the dry eye symptom and the sign of the ocular tissues could be well maintained. Overall, this study had demonstrated that the Controlled Discharge Xenon Flash Lamp device treatment is safe and effective in the treatment of dry eye caused by Meibomian Gland Dysfunction.

Read more

4 – Clinical trial in France, 2012 – 2015

Study:

Dr Christian Malbrel run a second clinical study in France on 55 patients who have been treated early 2012 with a surveillance over 36 months. Each patient received on average three E-Eye sessions.

Results:

The clinical study reveals that 62% of the patients didn’t experience any recurrence after the initial treatment during this period. 38% of them had to complete an additional session 7.5 months after the initial treatment. The average gap of surveillance without having to give another treatment was 29.3 months.

Testimonials

From the Ophthalmologist

‘‘I started using E-Eye in January 2014. It quickly became evident that patients were extremely happy with the results. In particular, patients with obvious rosacea were describing huge improvements in their ocular comfort and an improvement in their conjunctival injection. For a condition that previously had limited therapeutic options, IRPL is an exciting and highly effective new treatment modality for patients with dry eye from MGD.’’
Dr Brendan Cronin, MBBS (Hons), DipOphthSci, B.Com, LLB, FRANZCO

From the Optometrist

‘‘Not only my dry eye patients were happy with their E-Eye IRPL treatments but they also recommended their friends and relatives to get treated too and also this has become a very profitable service for my business. In fact, in less than 4 months I had achieved a return on my investment! There is no other ophthalmic equipment on the market with such a quick return and it definitely makes my practice stand out from the crowd. E-Eye is definitely the best piece of equipment that I have invested in. It is attracting on average 3 to 5 new customers per week and these customers are now coming to buy our frames and have their eyes examined.’’
John Veale, Optometrist
Customer satisfaction results 2015

From the patient

‘‘My eyes felt great after 3 treatments and continue to improve in regards to tolerance of airconditioning and computer use, especially after a long day. My eyes felt so much better I was finally encouraged to apply for a job and was successful. It would have not been possible a few months ago as I couldn’t even watch a computer screen for more than a few minutes.’’
Sofia, dry eye sufferer from Sydney.